IP Library › Granted Patent US 12,411,139
Granted Patent B2
US 12,411,139 · App. 18/242,804 · Granted Sep 9, 2025

Highly sensitive system and method for analysis of troponin

Inventors: Philippe J. Goix (Piedmont, CA); Robert Puskas (Manchester, MO); John Todd (Lafayette, CA); Richard Livingston (Webster Groves, MO); Douglas Held (Ballwin, MO); Allan H. B. Wu (Palo Alto, CA)
Assignee: Novilux, LLC
G01N33/68G01N21/6428G01N21/6486G01N33/582G01N33/6887G01N33/6893G01N2333/47G01N2800/32G01N2800/324G01N2800/325G01N2800/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,411,139
App. No.
18/242,804
Granted
Sep 9, 2025
Kind
B2
Abstract

The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.

Claims (28)

1. A method for determining cardiac damage in a human subject, comprising:

(a) determining concentration of cardiac troponin I (cTnI) in a blood, serum or plasma sample from the subject in an assay having a limit of detection for cTnI of less than 3 pg/mL by comparing a measured concentration of cTnI in the sample to a standard curve generated by running cTnI standards of known concentration in the assay;

(b) comparing the determined concentration of cTnI in the sample to a threshold concentration of cTnI in blood, serum or plasma in a healthy population, wherein the threshold concentration represents the 99th percentile of cTnI in the healthy population and is within the range of 1 pg/ml to 10 pg/ml, and wherein the threshold concentration determined by a method having a limit of detection for cTnI of less than 3 pg/mL;

(c) determining cardiac damage in the subject when the concentration of cTnI in the sample is greater than the threshold concentration.

2. The method of claim 1 , wherein the cardiac damage is a result of myocardial infarction, cardiac toxicity, acute coronary syndrome, myocarditis, or heart failure.

3. The method of claim 1 , wherein the assay has total imprecision (CV) of less than or equal to 10% at the threshold concentration.

4. The method of claim 1 , wherein the threshold is established at the 99th percentile with a corresponding total imprecision (CV) of less than or equal to 10%.

5. The method of claim 1 , wherein cardiac damage is determined when the threshold concentration of cTnI is about 7 pg/ml.

6. The method of claim 1 , wherein cardiac damage is determined when the threshold concentration of cTnI is about 8 pg/ml.

7. The method of claim 1 , wherein cardiac damage is determined when the threshold concentration of cTnI is about 9 pg/ml.

8. The method of claim 1 , wherein cardiac damage is determined when the threshold concentration of cTnI is about 10 pg/ml.

9. The method of claim 1 , wherein the sample is a whole blood sample.

10. The method of claim 1 , wherein the sample is a plasma sample.

11. The method of claim 1 , wherein the sample is a serum sample.

12. A method for determining cardiac damage in a human subject, comprising:

(a) determining a concentration of cardiac troponin I (cTnI) in a blood, serum or plasma sample from the subject in an assay having a limit of detection for cTnI of less than 3 pg/mL by interpolating the measured concentration of cTnI in the sample through a standard curve generated by running cTnI standards of known concentration in the assay;

(b) comparing the determined concentration of cTnI in the sample to a threshold concentration of cTnI in blood, serum or plasma in a healthy population, wherein the threshold concentration represents the 99th percentile of cTnI in the healthy population and is within the range of 1 pg/ml to 10 pg/ml, and wherein the threshold concentration determined by a method having a limit of detection for cTnI of less than 3 pg/mL;

(c) determining cardiac damage in the subject when the concentration of cTnI in the sample is greater than the threshold concentration.

13. The method of claim 12 , wherein the cardiac damage is a result of myocardial infarction, cardiac toxicity, acute coronary syndrome, myocarditis, or heart failure.

14. The method of claim 12 , wherein the assay has total imprecision (CV) of less than or equal to 10% at the threshold concentration.

15. The method of claim 12 , wherein the threshold is established at the 99th percentile with a corresponding total imprecision (CV) of less than or equal to 10%.

16. The method of claim 12 , wherein cardiac damage is determined when the threshold concentration of cTnI is about 7 pg/ml.

17. The method of claim 12 , wherein cardiac damage is determined when the threshold concentration of cTnl is about 8 pg/ml.

18. The method of claim 12 , wherein cardiac damage is determined when the threshold concentration of cTnI is about 9 pg/ml.

19. The method of claim 12 , wherein cardiac damage is determined when the threshold concentration of cTnI is about 10 pg/ml.

20. The method of claim 12 , wherein the sample is a whole blood sample.

21. The method of claim 12 , wherein the sample is a plasma sample.

22. The method of claim 12 , wherein the sample is a serum sample.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2025
From: SINGULEX, INC.
To: NOVILUX, LLC
Reel/Frame 071038/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2025
From: GOIX, PHILIPPE J.; PUSKAS, ROBERT; TODD, JOHN; LIVINGSTON, RICHARD; HELD, DOUGLAS
To: SINGULEX, INC.
Reel/Frame 070893/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2025
From: WU, ALAN H.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 070893/0604 →
Continuity (16)
Continuation 16842727 · Apr 7, 2020
Continuation 15660783 · Jul 26, 2017
Continuation 14921553 · Oct 23, 2015
Continuation 13798547 · Mar 13, 2013
Continuation 13667372 · Nov 2, 2012
Continuation 12902182 · Oct 12, 2010
Continuation 12062412 · Apr 3, 2008
Continuation 11784213 · Apr 4, 2007
Provisional Application 60914995 · Apr 30, 2007
Provisional Application 60925402 · Apr 19, 2007
Provisional Application 60872986 · Dec 4, 2006
Provisional Application 60861498 · Nov 28, 2006
Provisional Application 60808662 · May 26, 2006
Provisional Application 60793664 · Apr 19, 2006
Provisional Application 60789304 · Apr 4, 2006
Related Publication 20240085430A1 · Mar 14, 2024
References Cited (2)
US 20070249008A1 · Mallat · 2007 [cited by examiner]
US 20070269836A1 · McPherson · 2007 [cited by examiner]